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Abstract
The nature of the exposure-response relationship has a profound influence on risk analyses. Several arguments 
have been proffered as to why all exposure-response relationships for both cancer and noncarcinogenic end-
points should be assumed to be linear at low doses. We focused on three arguments that have been put forth 
for noncarcinogens. First, the general “additivity-to-background” argument proposes that if an agent enhances 
an already existing disease-causing process, then even small exposures increase disease incidence in a linear 
manner. This only holds if it is related to a specific mode of action that has nonuniversal properties—properties 
that would not be expected for most noncancer effects. Second, the “heterogeneity in the population” argument 
states that variations in sensitivity among members of the target population tend to “flatten out and linearize” the 
exposure-response curve, but this actually only tends to broaden, not linearize, the dose-response relationship. 
Third, it has been argued that a review of epidemiological evidence shows linear or no-threshold effects at low 
exposures in humans, despite nonlinear exposure-response in the experimental dose range in animal testing for 
similar endpoints. It is more likely that this is attributable to exposure measurement error rather than a true non-
threshold association. Assuming that every chemical is toxic at high exposures and linear at low exposures does 
not comport to modern-day scientific knowledge of biology. There is no compelling evidence-based justification 
for a general low-exposure linearity; rather, case-specific mechanistic arguments are needed. 
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Introduction
The process of conducting risk assessments for both physical 
and chemical agents has evolved over the past century and 
has increasingly become more formalized (McClellan, 1999; 
Albert, 1994). The United States Environmental Protection 
Agency (US EPA), in carrying out its statutory responsibili-
ties, has probably had greater impact than any other federal 
agency in fostering the use of risk assessment. The National 
Research  Council  (NRC,  1983)  has  offered  advice,  docu-
mented in numerous NRC reports, on the risk assessment 
process and how it should be used. The process is generally 
recognized  now  as  having  four  key  components  that  are 
traceable to the NRC (1983) report, “Risk Assessment in the 
Federal  Government:  Managing  the  Process”:  (1)  hazard 
identification;  (2)  exposure  (dose)-response  characteriza-
tion; (3) exposure assessment; and (4) risk characterization. 
A later NRC (1996) report, “Science and Judgment in Risk 
Assessment,” proposed that a feedback loop from identified 
uncertainties that might be reduced through further research 
be recognized as a fifth step in the process.
The  present  paper  addresses  the  important  second 
component  of  the  risk  assessment  process,  the  exposure 
(dose)-response characterization for an agent that has been 
characterized as hazardous. It is obvious that the results of the 
fourth step noted above, risk characterization, are depend-
ent upon “exposure characterization,” either as measured 
or estimated for a particular situation, and the nature of the 
“exposure (dose)-response” relationship.
The published literature and, indeed, most of the NRC 
reports on risk assessment, frequently refer to dose-response 
relationships or curves; linear dose-response relationships; 
linear, nonthreshold dose-response relationships; or non-
linear, threshold dose-response relationships or curves, all 
making use of the word “dose” in a wide variety of situations. 
In most cases, what is being described is better termed “expo-
sure,” because uptake and target-tissue levels are seldom 
directly addressed, and we will use this terminology in the 
present discussion. Moreover, the term “response” can be 
ambiguous, and we shall take it to mean the greater or lesser 
likelihood that a discrete case of the health effect is induced in 
an exposed subject by the exposure to the agent in question, 
with the question of how such responses relate to underlying 
continuous changes in causal biochemical or physiological 
processes, and how they may relate to the background rate 
of the same effect in unexposed populations as matters to 
explore in our discussion.
It is not surprising that, as the need arose for conducting 
risk  assessments  on  chemical  carcinogens,  the  approach 
taken was to borrow heavily from what was known about 
radiation  carcinogenesis  (Albert,  1994;  McClellan,  1999). 
Indeed, today a cornerstone of assessing the carcinogenic 
risks of chemicals is that if the chemical or its metabolites 
cause gene mutations by interacting directly with DNA, they 
cause cancer in a manner analogous to radiation, and the 
dose-response relationship for the chemical can be assumed 
to have a linear, no-threshold relationship. The debate still 
continues regarding whether this default assumption should 
or should not be extended to chemicals that are not DNA-
reactive and yet cause cancer, typically with protracted high 
levels of exposure in laboratory rodents.
The debate over the nature of the exposure (dose)-response 
relationship has now been extended from cancer as the health 
endpoint to a wide range of noncancer endpoints. These 
include respiratory and cardiovascular morbidity and mortal-
ity. A major stimulus for this debate has been the increased 
attention given to a group of air pollutants regulated by US 
EPA under the Clean Air Act as criteria pollutants for which 
National Ambient Air Quality Standards (NAAQS) must be 
established. The criteria pollutants include particulate matter 
(PM), ozone, carbon monoxide, nitrogen oxide, sulfur diox-
ide, and lead. With sufficiently high levels of exposure, all of 
these pollutants increase the occurrence of noncancer health 
effects, such as respiratory diseases, over the background 
rate. A critical question that arises in developing NAAQS for 
each of these pollutants is the risk at low levels of ambient 
exposure.
The debate over the nature of the exposure (dose)-excess 
effect relationship for noncancer endpoints has been brought 
to the forefront by two recent publications. A paper by White 
et al. (2009) describes the conclusions of an ad hoc panel of 
nine individuals who addressed “issues and approaches in 
low  dose-response  extrapolations.”  Several  of  the  partici-
pants in that endeavor served on the NRC committee that 
prepared  the  report,  “Science  and  Decisions:  Advancing 
Risk Assessment” (NRC, 2009). That report proposed three 
options for extrapolating low-dose risks of both carcinogens 
and noncarcinogens (conceptual models 1, 2, and 3). Model 
1 proposes thresholds for some individuals, but not on a 
  population basis. Model 2 proposes both individual and pop-
ulation thresholds. Model 3 proposes linear and nonthreshold 
responses for the individual and the population. In practice, 
one must essentially ascertain that the chemical’s effects do 
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not follow any of the mechanisms that are posited as causing 
linearity to accept it as Model 2. In practice, it is likely that this 
will almost always lead to the adoption of either Model 1 or 3, 
both of which assume linearity at the population level.
The  question  about  the  appropriate  presumptions  to 
make about exposure-response patterns at exposures below 
those at which frank toxicity is readily observed has a long 
history of discussion. Many points continue to receive vigor-
ous discussion, as proffered general principles, as bases for 
science policy decisions and default approaches, and in the 
risk assessment of particular agents and toxic effects. In the 
present paper, we focus on one newly salient aspect of this 
debate—whether agents causing noncancer toxicity at high 
exposure levels should, as a general principle or a default 
stance, be presumed to cause some degree of risk of these 
same endpoints at any positive dose, no matter how low.
Adopting  this  view  for  noncancer  endpoints  could 
amount  to  abandoning  thresholds  as  a  tenet  of  biology, 
pharmacology,  and  toxicology,  and  abandoning  the  no 
observed  adverse  effect  level  (NOAEL)/uncertainty  fac-
tor  (UF)  approach  to  characterizing  acceptable  levels  of 
exposure to agents causing high-dose toxicity. Although we 
understand the usefulness for risk management purposes of 
continuous measures of increasing or decreasing expected 
impact of an agent on public health as control measures are 
contemplated, we fear that a hastily adopted approach that 
assigns some level of risk of induction of full-blown cases 
of the health effects seen at very high exposures to all lower 
exposures will be destructive of the credibility of quantitative 
risk analysis. Moreover, we find such a blanket approach sci-
entifically unjustified, and the balance of this paper presents 
our reasoning for thinking so.
The arguments proffered as to why all exposure-response 
relationships should be assumed to be linear include (1) the 
general “additivity-to-background” argument, which assumes 
that if an agent enhances an already existing disease-causing 
process, then even small increases in exposure concentra-
tion and/or duration increase disease incidence in a linear 
manner; (2) the “heterogeneity in the population” argument, 
which assumes that variations in sensitivity among members 
of the target population tend to “flatten out and linearize” the 
exposure-response curve; and (3) a review of epidemiological 
evidence supposedly showing linear or no-threshold effects 
at low exposures in humans, despite nonlinear dose-response 
in the experimental range in animal testing for similar end-
points (NRC, 2009; White et al., 2009). (These three arguments 
were initially laid out by NRC [1977], but that report noted 
that additional lines of reasoning and additional assump-
tions need to be recognized in considering the arguments for 
linearity. Other arguments have been put forth, such as that 
receptor-mediated endpoints have no threshold. Although we 
do not agree with this tenet, exploration is beyond the scope 
of the present discussion.1) Below, we raise questions about 
the transparency, completeness, and scientific validity of each 
of these arguments for the following reasons: (1) the principle 
of additivity to background disease processes fails to support 
linearity unless it is related to a specific mode of action that 
has some nonuniversal properties—properties that would 
not be expected for most noncancer effects; (2) although 
heterogeneity in sensitivity and in modifying factors among 
people in a human target population may tend to broaden the 
dose-response relationship, they do not linearize it; and (3) 
exposure measurement error in epidemiological studies can 
lead to an apparent linear exposure-response relationship, 
when the true relationship is nonlinear or threshold.
Framing the problem
Before beginning our discussion, it is useful to sharpen the 
question. In our experience, clear and productive discourse 
on these issues is often hampered by the lack of a common, 
generally agreed-upon framework and terminology. The low-
dose linearity thesis for noncancer toxicity as set out in the 
“Science and Decisions” report (NRC, 2009) and in White 
et al. (2009) is put forth in general terms and is taken to be 
broadly (if not universally) applicable. Their arguments for 
low-dose linearity are based not on specific observations 
about specific chemicals and their modes of action, but rather 
on a proposed broadly operating argument-in -principle—on 
an assertion that, in their view, some very general and plau-
sibly applicable biological processes underlie apical toxicity 
generation, which should be expected to lead to small incre-
ments in the probability of response at any positive dose 
level, no matter how small. Assertions are being made about 
the logical expectations regarding the existence of risks that 
are well below the observable parts of dose-response rela-
tionships. Therefore, in aiming for compelling and broadly 
applicable analysis, their arguments must be cast in terms of 
general principles about what ought to be expected regard-
ing the interaction of very low levels of a chemical with the 
toxicity-generating process. As a consequence of this, our 
own arguments and critiques must be expressed in similarly 
general terms.
In this context, the apical effects under discussion are 
quantal effects—ones that are either present or absent—
rather than continuous measures such as blood pressure 
or liver weight. That is, the “response” in the proposed low-
dose-linear dose-response relationship is the probability that 
an individual would be scored as having developed the apical 
effect as a consequence of exposure. On a population level, 
it is the expected fraction of a population that would show 
the effect. As will be discussed below, however, even though 
the apical endpoints are quantal, their asserted increase in 
frequency of appearance at very low doses depends on argu-
ments about how those doses quantitatively perturb under-
lying continuous physiological states, and further, how such 
small perturbations of underlying continuous variables lead 
to generation of the quantal apical toxicity of concern. That 
is, the crux of the matter is the conception of how underlying 
continuous biological variation—as quantitatively perturbed 
by  small  exposures—produces  discontinuous  transitions 
from a healthy to a diseased state. Because our subject is 
1A recent workshop focused on this issue; see http://www.tera.org/Peer/
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the nature of this connection, it is necessary for us to address 
how  small  doses  affect  underlying  continuous  variables, 
but the reader should bear in mind that these perturbations 
are not themselves the apical responses in question, which 
remain as “cases” of a recognizable and discrete dysfunc-
tional state.
For discrete outcomes, the dose-response curve represents 
the change in probability that an individual will respond to a 
given dose by becoming a case. In this context, “probability” 
refers to the expectation that a randomly chosen individual 
exposed at a given level will be found to be a responder. In 
cancer risk assessment, we often treat all individuals as of 
equal inherent susceptibility, and the probability of respond-
ing with a chemically induced tumor is treated as stochas-
tic—a matter of chance that is not probed for the underlying 
reasons as to why one subject responds and another similarly 
exposed one does not. That is, the “probability” of apical out-
comes enters for each individual as a stochastic phenomenon 
at the most fundamental and causative level accessible to our 
conceptional approach. In the present context of noncancer 
toxicity, however, we are instead dealing with underlying 
physiological differences among individuals that constitutes 
the basis of interindividual variations in susceptibility. The 
overtly observable dose-response pattern is seen as emerging 
from the interaction of such variation with the doses and with 
the disease-generating process. In particular cases, one could 
imagine getting information on this underlying variation in 
causal processes and using it to make deterministic models 
of apical-toxicity generation that results in subject-by-subject 
determinations of who responds and who does not. If this 
modeling were perfect, there would be no stochastic element 
involved—any particular subject’s outcome could be calcu-
lated from the model—and in a population of randomly cho-
sen individuals, what would vary with dose is the proportions 
of them listed in the responder and nonresponder columns. 
When one speaks of “probability” of response in this context, 
one is referring to the chance that a randomly chosen indi-
vidual of unknown susceptibility is found to be susceptible 
enough to be a responder at the dose in question. In practice, 
one cannot really create an infallible deterministic model, 
and so the distinction between known-but-varying causes 
and randomly acting causes breaks down. It is an interesting 
philosophical debate, beyond the scope of the present paper, 
to consider whether unknown-but-deterministic causes con-
stitute “chance,” how this may or may not differ from “true 
stochasticity,” and how the answer should affect the conduct 
of dose-response analysis. It should be clear, however, that 
in the present paper, we are addressing the NRC (2009) and 
White et al. (2009) consideration of hypothetical underlying 
causes of susceptibility cast in very general terms, critiquing 
their analysis of how such variation should lead to low-dose 
linearity. Accordingly, we must do as they have done, playing 
both sides of the “known or unknown causes” issue to see 
how they relate. That is, one hypothesizes underlying sus-
ceptibility variation and assumes knowledge of it (including 
variation among individuals) to make arguments about the 
spectrum of outcomes it should generate; then, one imagines 
an analyst faced with data on apical outcomes and at most 
only partial understanding of the particulars of those same 
toxicity-generating processes, especially on the level of their 
variation in particular identified individuals. The aim is to 
make conclusions about how that analyst should analyze 
the probability of response, including expectations about the 
probabilities at doses too low to observe outcomes directly. 
The outcomes are probabilities because the analyst does not 
share the omniscient point of view about the hypothesized 
toxicity-generating process.
“Low-dose  linearity”  of  such  dose-response  relation-
ships, then, refers to the notion that small doses, no mat-
ter how small they may be, should be expected to result in 
some incremental increase in the probability of response (as 
probability is defined above), over and above any responses 
that would have happened in any case even in the absence 
of those small exposures. That is, it is an assertion of the lack 
of a population exposure threshold for the increase in risk of 
an induced effect. (As we will discuss below, the argument 
as presented by NRC [2009] and White et al. [2009] actually 
appears to require that individual thresholds exist—doses 
below which a given subject will not respond—as a way to 
generate the discontinuous jump from unaffected to affected 
at the level of the quantal apical endpoint. But low-dose lin-
earity asserts that there is no population threshold, meaning 
that there will always be some individuals having personal 
thresholds of zero, and so they will respond to any increment 
of dose no matter how small.)
As formulated in NRC (2009) and White et al. (2009), the 
argument for existence in principle should apply equally to 
animal and human dose-response curves. Nonetheless, if one 
were to accept this principle and use it in formulating science 
policy for human health risk assessment, one would need to 
address the fact that, because the origin of the linearization 
effect resides in the patterns of interindividual variability and 
the nature of the background disease processes with which 
low doses interact, the application of the principle to human 
health risk estimation would need to rely on inferences and 
understanding about background disease rates and processes 
in the target human population, and animal dose-response 
curves,  their  shapes,  and  their  low-dose  extrapolations 
would have little to say about this subject. Even the animal 
endpoints would be relevant primarily as providers of hazard 
information about the interaction of the agent with human 
background disease processes.
The assertion of low-dose linearity applies to the very bot-
tom of the dose-response curve—that is, that at zero dose, 
the first derivative of the curve is positive. (Theoretical no-
threshold  dose-response  curves  exist  that  approach  zero 
asymptotically and so have zero slope at zero dose, but the 
low-dose linearity claim is that small increments of dose over 
zero immediately produce a linear increase in risk.) The claim 
is not that this linearity at the lowest doses necessarily results 
in a continued linear shape at higher doses; that is, it is not 
necessarily so that an overall linear shape is expected between 
the very low doses and the beginning of response rates that are 
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response should be expected among the dose levels observed 
in experiments. Hence, observed nonlinearity in empirical 
results does not preclude or refute the possible existence of 
a low-dose linear component near zero dose. Strict linearity 
(i.e., lack of curvature, not merely positive slope) prevails only 
if higher derivatives of the curve near the origin are zero, and 
they may be nonzero, but even in this case, small increments 
in dose will produce nearly linear small increments in risk (as 
can be shown by a Taylor Series expansion) as long as the first 
derivative is positive (and the limits to how small the dose 
range needs to be to preserve near-linearity depends on the 
values of higher-order derivatives).
We mention these technicalities to be clear about what we 
are discussing, but there is a very practical aspect. Although 
the  discussion  in  the  risk  assessment  community  about 
the arguments in NRC (2009) and White et al. (2009) have 
focused on broad principles, the apparent intent of the NRC 
panel with regard to the practicalities seems to have been lost. 
The report states (p.131), “Note that low dose linear means 
that at low doses ‘added risk’ (above background) increases 
linearly  with  increasing  dose;  it  does  not  mean  that  the 
dose-response  relationship  is  linear  throughout  the  dose 
range between zero dose and the high dose.” The associated 
figure in the report (Figure 5-6) shows clear nonlinearities 
in the range from the data to zero. We agree with the NRC 
(2009) authors on this important point. Even if one were to 
agree with the NRC (2009) assertion of low-dose linearity for 
classical noncancer endpoints, this does not mean that it is 
appropriate to estimate risk by drawing a straight line from 
a point of departure to zero. The question then arises about 
how one would obtain information regarding the magnitude 
of the theoretical low-dose linear risk component. The NRC 
(2009) report provides only minimal ideas in this regard, and 
it does not address how to extrapolate downward from high 
doses—that is, how far below the lowest observed doses one 
might go with a markedly nonlinear extrapolation until one 
reaches the “low” dose range at which the hypothetical forces 
causing linearity come to predominate over other influences 
on curve shape.
Thus, although we agree with the NRC panel that low-
dose linearity does not imply linear extrapolation from a 
toxic effect level, the implications of this statement need 
further discussion in the risk assessment community. Since 
the assertion of low-dose linearity of noncancer-effect dose-
response curves is about the existence of a linear compo-
nent at the very lowest doses—and not about its magnitude, 
about the range of doses over which linearity is expected, 
or about the shape of the curve at places other than near 
zero dose—the role of this principle (even if it were to be 
accepted) in practical noncancer risk assessment is a mat-
ter needing much further consideration. Such discussion 
is beyond the scope of the present paper, but some of the 
issues have been discussed elsewhere (Rhomberg, 2010). 
For the present, we wish to address the question of whether 
low-dose linearity (in the particular sense of the term as we 
have tried to define it above) should be presumed to exist 
for quantal noncancer toxicity apical endpoints, either as a 
general rule applicable to all or most effects, or at least as a 
likely and frequent effect that is sufficiently prevalent that it 
might be taken into account in formulating risk assessment 
science policy.
The further question of whether, as a matter of science 
policy for risk analysis, human risks at low doses ought to 
be estimated using some form of linear extrapolation from 
higher doses—on the grounds that linearity near the origin 
may exist or at least cannot be dismissed as possible—is a 
topic for later discussion. But this further discussion cannot 
be pursued productively until the question of the expected 
existence of linearity near the origin is better understood, and 
this narrower question is the focus of the present paper.
Additivity to background
The general principle of the additivity-to-background argu-
ment is that if an agent to any degree enhances the underlying 
pathobiological process or perturbs the level of some under-
lying state that is sufficient as a genesis of the background or 
“spontaneous” cases of disease, then the incremental effect 
of small increases in exposure to that agent will be a linear 
increase in response rate over background in the population. 
The argument was initially proposed by Crump et al. (1976) 
for application to genotoxic carcinogens. More recently, it has 
also been suggested to be applicable to common noncancer 
endpoints, first by Crawford and Wilson (1996), who noted 
that, if background cases of the endpoint in question (those 
appearing in unexposed individuals) are considered to be 
manifestations of the same process that, through its accelera-
tion by exposure, leads to observed toxicity at higher doses, 
then an argument similar to that put forth by Crump et al. 
(1976) could apply. Crawford and Wilson (1996) treated the 
noncancer toxicity as a quantal endpoint appearing with a 
probability characterized by a dose-response that implicitly 
uses as its “dose” measure the intensity of the underlying 
toxicity-generating  process.  The  existence  of  background 
cases is then attributed to the native nonzero level of intensity 
of this process in the absence of exposure to the chemical in 
question; in other words, the point of zero dose of the agent in 
question corresponds to a nonzero, positive level of intensity 
of the underlying toxicity-generating process, and hence the 
unexposed population is already somewhat “up the curve” 
from its origin at a level of zero for the ordinate (the probabil-
ity of response) and zero for the abscissa (the a intensity of the 
underlying causative process). If one presumes a continuous 
and monotonically increasing dose-response relationship, the 
incremental response over background at doses just above 
zero exposure to the chemical will be approximated by the 
tangent to the curve at zero dose, which will always be posi-
tive and, at least for very small doses, linearly increasing.
Crawford and Wilson (1996), and similar approaches that 
have followed, presume a connection between underlying 
biological processes, their perturbation by small increments 
of exposure, and the probability of generation of a new case 
of the endpoint in question, but they have not probed its 
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toxicity effects are engendered not by rare all-or-none events 
(such as mutations), but rather as emergent consequences 
of patterns of changes of sufficient magnitude in continu-
ous  physiological  variables,  through  which  homeostasis 
and defensive processes that keep organisms functioning 
normally even in the face of environmental fluctuation are 
overcome,  then  the  means  for  turning  small  quantitative 
physiological changes into overt and recognizable cases of 
frank disease are not necessarily simple. In our view, a pre-
sumption that a little more chemical leads to a little more 
probability of effect is not self evident and needs careful con-
sideration. (Noncancer effects that occur via a mode of action 
that involves direct DNA interaction may well have exposure-
response relationships that are similar in shape to those for 
classical carcinogens, but most noncancer endpoints result 
from interaction of the chemical with proteins or other cellu-
lar constituents.) Proponents of the additivity-to-background 
argument for such endpoints propose that heterogeneity in 
the human population leads some individuals to be at the 
margins of acceptable levels of such underlying physiologi-
cal variables, and that the background rates of disease are 
explicable, at least in part, by the hypothesized existence of 
individuals who, even without chemical stressors, have values 
of the underlying variables that are insufficient to maintain 
health.
The  additivity-to-background  argument  was  raised  to 
justify the adoption of a linear-at-low-dose approach as a 
general principle to be applied to all toxicants and toxicity 
endpoints regardless of case-specific data (White et al., 2009). 
Appropriate consideration of this hypothesis requires articu-
lation of the statistical and biological assumptions (many of 
them implicit) on which this approach is predicated. This 
includes identification of the assumptions about the nature of 
the “background processes” and background disease, about 
the nature of human heterogeneity and its relation to healthy 
and diseased states, and about the effect of small chemical 
doses on the biological system.
What makes additivity to background risk plausible for 
genotoxic carcinogens is the discrete and stochastic nature 
of both the mutational changes and the malignancy-bearing 
endpoint of concern—each mutation happens all-or-none 
and not by degrees. Also important is the single-molecule 
nature of the component processes, which makes possible 
the jump from state to state in individual genes borne by indi-
vidual cells. Finally, events at the molecular level in a single 
cell can, owing to the proliferation of a resulting malignantly 
transformed cell through a series of cell divisions, develop 
into a life-threatening tumor that manifests itself as a full-
blown case of disease at the whole-organism level. Thus, 
there is a process that amplifies the single-molecule, single-
cell events into a disease that affects the whole organism. 
In contrast, for noncancer toxicity, the disease endpoints of 
interest consist of structural and/or physiological failures of 
systems at the whole-organism level. Individual molecules 
or cells are only important insofar as they constitute minute 
fractions of the overall process acting among many cells and 
molecules, the sufficiency of the collective function of which 
is the key to whether disease occurs. The noncancer health 
effect endpoints themselves vary in severity. Categorizing 
individuals into those with or without the health effect (and 
thereby defining the rate of quantal “response” to be charac-
terized by the exposure-response analysis) may involve an 
arbitrary demarcation between normal and marginal cases. 
The underlying causal processes are also graded, so there is 
no discrete jumping from state to state. (There may be recog-
nizable stages and key events in the progression of the dis-
ease process, but they are landmarks in a continuum rather 
than changes between discrete states such as normal versus 
mutated.) Despite this underlying continuum of causal proc-
esses, we recognize apical toxic effects as marked departures 
from and alteration of the normal and healthy state. Apical 
toxicity involves more than being in the tails of distributions 
of normal states; it entails dysfunction and a cascade of physi-
ological failures with multiplying consequences. Unlike muta-
tions, where the change of state is a single molecular event at 
a single locus, the generation of noncancer toxicity is a com-
plex process of interacting forces acting throughout the tissue 
and the organism. This toxicity reflects an emergent property 
of control networks—or rather of the failure of those control 
networks—that, instead of dissipating and ameliorating per-
turbations, come at a certain level to amplify them. We use 
the concept of a threshold to recognize at a phenomenologi-
cal level that some values of underlying physiological states 
maintain normal control and function, whereas others lead 
to lack of control and dysfunction that is discontinuous with 
the range of normal variation, even though the magnitude 
of the excursion from normal states may vary among cases. 
The challenge for noncancer toxicity dose-response assess-
ment is to account for how the modest degrees of underlying 
continuous variation are translated into more or less discrete 
differences between healthy and diseased states.
The logic of additivity to background disease risk is there-
fore not a direct translation from the genotoxic carcinogen 
case; one must consider how noncancer effects arise, what 
accounts for the appearance of background cases, what is 
changed by the introduction of a toxic agent, and how such 
an agent is thought to increase the marginal rate of appear-
ance of disease. Despite this lack of equivalence to genoto-
xic carcinogens, some arguments entailed in how induced 
cancers  might  relate  to  the  endogenous  disease  process 
are valuable to note and may apply to noncancer effects, 
albeit in a somewhat altered way: (1) the effect that appears 
in unexposed individuals (and is being added to) must be 
the  same  in  underlying  pathological  process  and  in  ulti-
mate manifestation as the effects induced by exposure; (2) 
background rates of all needed processes occur even in the 
absence of exposure; (3) these account for the appearance of 
the full apical effect as a background rate among the unex-
posed; (4) even small exposures produce changes in the rates 
or magnitudes of these processes from what they would be 
absent such exposure; and (5) the small changes so induced 
are sufficient to provoke a discrete overall change in health 
state of the organism from normal or healthy to affected or 
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of additivity to background as it would apply to noncancer 
toxicity influenced by alteration of underlying continuous 
physiological states, asking whether the implicit assump-
tions about the nature of the underlying action of noncancer 
toxicants and of any consequent adverse effects are indeed 
in accord with our understanding of toxicological processes 
for such endpoints.
The  notion  presented  by  proponents  of  additivity  to 
background risk for noncancer toxicity is that there is some 
key physiological variable or state that varies continuously 
among individuals. A poor value of this state produces the 
disease endpoint in question. In essence, there is a threshold 
value for the internal state, beyond which the frank disease 
endpoint occurs. The background rate of disease (to which 
the chemically induced component adds) is attributed to 
some individuals having a value of the key underlying vari-
able that is beyond the cut-off level for health, and so they 
have the disease. That is, the background rate of disease 
occurs because some individuals are beyond the threshold 
value for the internal factor even in the absence of the toxic 
agent in question. The agent in question is seen as margin-
ally shifting the distribution of the underlying variable among 
members of the population such that some individuals who 
were formerly just marginally adequate for the physiological 
parameter are now just beyond the threshold and therefore 
the disease develops. According to this view, then, an amount 
of  exposure,  however  small,  shifts  the  distribution  of  the 
internal physiological state, however slightly, and leads to at 
least a small number of population members to transition 
from the healthy to the diseased state. For small increments of 
exposure, the change in risk should be approximately linear 
in relationship to increased exposure.
When presented as an argument in principle (rather than 
as an interpretation of case-specific observations), the iden-
tity of the “internal state” or “key physiological variable” is 
not specified. It is presented as a hypothetical embodiment 
of the additivity-to-background premise regarding the chemi-
cal’s ability to enhance or perturb the same processes that 
lead to background cases of the disease among unexposed 
individuals. That is, it is something that varies among indi-
viduals, for which such variation accounts for the existence 
of background cases in the absence of exposure, for which 
small changes are sufficient in at least some individuals to 
move them from being without the apical endpoint to hav-
ing the apical endpoint, and for which very small exposures 
to the chemical will indeed produce those small changes. In 
evaluating the plausibility and hypothesized generality of 
this argument—and its comportment with our understand-
ing and observations of underlying biology and noncancer 
pathogenesis—it is important to identify the specific proper-
ties that such underlying variables and endpoint-generating 
toxicological processes must have for the logic of additivity 
to background to operate. Moreover, if these principles are 
to be used to address whether risks to humans at low expo-
sures are to be expected for hazards identified at much higher 
doses, and in animal tests rather than in humans, then some 
particular correspondences need to exist between the causal 
processes at such high doses in animals (where the potential 
hazard is identified) and very low doses in humans (where 
the potential for impact of that hazard is being inferred). In 
particular:
1.Certain particular values of the underlying physiological 
variable or state must be sufficient to cause the presence 
or absence of the disease in question. That is, falling 
beyond a threshold value is enough to cause someone 
to become a responder. (Otherwise, the crossing of the 
threshold would not produce an additional case.)
2.There  must  be  a  background  incidence  of  disease  in 
the population even without exposure to the causative 
agent in question, and this must be the same disease 
state, with the same pathogenesis, as the responses seen 
with  high  concentration  and/or  long  duration  expo-
sures to the agent in question. That is, the agent must 
increase the disease rate by shifting the distribution of 
the underlying physiological variable or state, and cross-
ing the threshold must mean the same thing with the 
same consequences throughout the dose range and for 
human and animal. In other words, some fraction of the 
population is already beyond the threshold value of the 
internal state, and the physiological or structural failure 
that constitutes the disease endpoint must therefore be 
present as a natural and inescapable part of the popula-
tion variation.
3.Moreover, for application of animal toxicity data to human 
health risk assessment, the background of human dis-
ease (to which the agent is imagined to be adding) must 
be pathologically equivalent to the induced effect in ani-
mals in the sense that development of adverse outcomes 
is contingent on the same small changes in underlying 
physiology. (If this is not so, then there is no biologically 
equivalent human background to add to.)
4.Many of those who do respond with the disease are only 
slightly different in their key internal state variable than 
other members of the population who, by being just on 
the other side of the threshold, are deemed healthy. If the 
healthy and diseased states for the endpoint in question 
seem qualitatively distinct, there must be markedly non-
linear processes that, once triggered, cause an individual 
just marginally different in the underlying causative vari-
able to develop the full disease and become distinct from 
others with only slightly different values of the internal 
state.
5.Even small amounts of the agent in question are capable 
of shifting the distribution of the internal state or physi-
ologic variable. That is, it is assumed that the agent can 
affect the value of the internal variable without a thresh-
old. Put another way, the body is unable to offer effective 
resistance to even small further impingements by chemi-
cal agents on the internal state variable in question.
 As the discussion above makes clear, the added risks being 
asserted at low exposure levels are a population phenom-
enon; any particular individual faced with a low exposure 
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it (and become a case), depending on how close the preex-
isting internal state was to the threshold for generating the 
apical response. Indeed, the additivity-to-background argu-
ment relies on the existence of thresholds on the individual to 
account for the genesis of new cases of the apical effect with 
only small changes in internal state. (Whether the threshold 
internal state for a response remains constant for the popula-
tion and individuals vary in how close to it they are and how 
much a given dose alters their internal state or whether one 
considers the threshold to vary among individuals is largely 
a matter of how one defines the terms; for the generalized 
case, these are equivalent, but if one is examining actual 
internal states and values of relevant physiological factors, 
the distinction becomes important. This issue could arise in 
applying any presumed general principle to actual disease 
processes.) Seen this way, it is clear that the core assertion of 
the additivity-to-background argument (and a possible route 
to evaluating its biological plausibility) is that the distribution 
of individual thresholds (or equivalently, the distribution of 
internal states vis-à-vis a fixed threshold) goes all the way 
down to zero thresholds and zero tolerance for further altera-
tion for some part of the population. Indeed, the distribution 
goes even “lower” in the sense that background cases of the 
endpoint in question, those appearing even in unexposed 
individuals, are attributed to their having values of internal 
states and personal thresholds such that, even if one could 
perturb the internal state a small amount in the direction 
opposite to that produced by the chemical, those individuals 
would still develop the apical toxicity in question. When the 
application is to human risk estimation from observed toxicity 
on animals (as is often the case), there is the further assertion 
that the pathophysiological processes that led to the toxicity 
observed in high-dose animals also exist to some degree in all 
humans, that at least in some humans, they are of sufficient 
magnitude to generate the same kind of toxicity even without 
the chemical, and that in others, they are of nearly sufficient 
magnitude and need but a small increment to lead to the 
generation of the full apical effect in those people.
Of course, the properties needed for the action of non-
cancer agents causing noncancer effects, and for the nature 
of background incidence of the same endpoints, could be 
true. But it is important to evaluate the needed properties in 
view of what we have usually understood about the nature of 
the disease processes for noncancer endpoints. Below, we 
raise relevant considerations that lead to the understanding 
that the needed properties of toxicity-generating processes 
required for additivity to background for noncancer end-
points are not, in fact, generally expected, and indeed are not 
in accord with our understanding of normal physiology and 
the degree of its variation among individuals in the human 
population.
In fact, when we examine noncancer toxicity of agents, 
including examination of the changes in subjects without the 
fully developed endpoint in question, we see a progression of 
stages of increasing impact, and it is not only the final frank 
effect that shows dependence on exposure level or duration. 
Pathologists examining such effects recognize a cascading 
series of ever more consequential failures to maintain normal 
status in the face of ongoing chemical assaults, but at lower 
exposure levels, the precursor stages are not merely rarer, 
they are less severe or (at sufficiently low exposures) entirely 
absent.  It  is  not  until  earlier  stages  become  sufficiently 
advanced and inherent resistance to alteration overcome that 
subsequent stages are triggered. Moreover, we do not see a 
continuous gradation in human populations between those 
few who are fully healthy and those who have varying degrees 
of advancement of these underlying precursor processes, 
awaiting only a small chemically induced push to develop 
into full-blown disease. That is, it is not clear that pathobio-
logical progression of states seen to underlie toxic effects in 
test animals at high doses has a counterpart in humans who 
are not exposed or exposed only to much smaller amounts. 
The  needed  assumptions  for  additivity  to  background  to 
operate—that such people “on the verge” of becoming overt 
cases of adverse outcomes exist, and that their states are 
continuously graded with a larger population having only 
slightly better internal states (so that a slightly larger push 
will push a slightly larger fraction of the population over the 
threshold)—do not comport with our general observations. 
Since the gradation of severity of pathology and the need for 
extreme values of precursor states to generate cases of overt 
adverse outcomes do indeed appear in animal toxicity stud-
ies, the lack of something comparable in the general human 
population calls into question the needed equivalence of the 
pathobiological processes to justify the conclusion that small 
changes in human exposure would generate added cases of 
the outcome observed at high animal doses.
An  additional  consideration  of  the  additivity-to  -
background argument for low-dose linearity relates to the 
issue of “background” exposure, as opposed to background 
physiological state. This consideration suggests the potential 
for the “background” exposures of other toxicants to bring 
the dose-response for an individual chemical (which is bio-
logically nonlinear overall) into the linear range for a human 
population,  as  noted  by  US  EPA  (2005)  and  NRC  (2008). 
But this distinction does not affect the principle, since the 
contribution of background exposures, if they constitute the 
cause of the background to be added to, must be through 
effects on the same distribution of the internal physiologi-
cal variable. That is, the background exposures are simply 
among the reasons for why the “background” distribution of 
the internal state is as it is. In any case, as discussed more fully 
by Dourson and Haber (2010), such “background” exposure 
to other chemicals is more explicitly addressed as part of a 
mixtures or “combined exposures” assessment, which is rou-
tinely done by scientists based on guidelines from a number 
of organizations (e.g., ACGIH, 2006; US EPA, 1986, 2000, 2009; 
IPCS, 2009).
In a credible exposure-response assessment for mixtures 
or  combined  exposures  drawing  maximally  on  available 
data based on the toxicity of components as suggested by 
US EPA (1986, 2000) guidelines and frameworks of interna-
tional organizations (IPCS, 2009), however, the exposure-
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least as currently formulated) incorporate considerations of 
background exposures to other similarly acting chemicals. 
Rather,  a  mixtures  exposure-response  assessment  should 
be conducted on the mixture of concern, or on a sufficiently 
similar mixture. Absent such information, the mixture dose-
response assessment should be based on the dose-response 
assessments of individual chemicals, and these assessments 
on individual chemicals cannot in themselves incorporate 
background exposures to other chemicals.
The no-threshold proposal for noncancer toxicity is 
at variance with decades of experience in observing 
exposure-response relationships in pharmacology and 
toxicology, both within and below the usual experimental 
range for environmental chemicals
The idea that toxic effects have exposure thresholds below 
which the challenge posed by the agent is insufficient to 
cause an adverse response is fundamental to the science of 
toxicology and has been so for decades (Gallo, 2008; Rodricks 
et al., 2007; Eaton and Gilbert, 2008; Aldridge, 1986; Gehring 
et al., 1978; Clark, 1937). It is the same first principle that 
forms the basis for pharmacology and serves as a basis for 
the  use  of  pharmaceuticals  in  medical  therapy  (Dorato 
et al., 2007; Parascandola, 1981). This enormous weight of 
experience and observation cannot be overturned lightly. 
It is not simply that doses without added incidence of frank 
diseases are commonly observed; it is also that pathological 
investigation of changes at the underlying molecular, cellular, 
and physiological levels show that the impacts of chemical 
exposure are progressively attenuated at lower exposures 
until exposure levels are reached at which no structural or 
functional abnormalities are seen. That is, the effects not 
only become less common with progressively lower doses, 
they also become less severe, or even adaptive, until a level of 
interaction of a substance with a biological system is reached 
that has no ability to perturb the tissues in question from their 
normal function. This is not a matter of mere assertion on 
principle; it is based on massive amounts of repeatable obser-
vation (Calabrese and Baldwin, 2003; Calabrese and Blain, 
2005; Cohen, 2002).
The no-threshold idea is also belied by our experience 
with medicines, poisons, foodstuffs, and many other kinds 
of exposure to agents that can have toxic effects if experienced 
in excess. With the possible exception of allergic reactions, 
within the range of low exposures, we do not observe slightly 
increased exposures to such agents somewhat increasing the 
probability that we will suffer the full effect of a toxic dose. In 
therapeutics, a small fraction of the therapeutic dose will not 
necessarily produce a moderate or full response in a dimin-
ished fraction of the treated population. It is only when the 
critical concentration is sustained at the site of action for 
the necessary period of time that an effect will be elicited. 
The experience of exposure thresholds for biological effects, 
including adverse effects, pervades daily life.
Indeed,  the  very  notions  of  “toxicity”  and  “pathology” 
would not exist if there were basic and gradual continuity in 
the properties of tissues and physiology between a healthy 
state and a diseased one. Conversely, the very notion of “nor-
mal” and “healthy” would not exist if it were impossible to 
recognize a qualitative (and not merely a graded) distinction 
between affected and unaffected tissues. In short, the notion 
that the underlying determinants of and progression toward 
frank overt disease vary continuously in the whole popula-
tion, that the background incidence of frank disease reflects 
only being in the tail of such a distribution, and that such 
individuals differ only in degree from a substantial number 
of others who have an underlying pathology not yet severe 
enough to count as cases of disease is not in accord with our 
general experience or our observation of the underlying states 
of tissues and physiology.
This is most evident with severe acute toxic effects. For 
example, acute arsenic poisoning can be lethal (Levin-Scherz 
et al., 1987; Campbell and Alvarez, 1989; Quatrehomme et al., 
1992; ATSDR, 2007). The amounts required to produce such 
effects are much greater than usual human exposures, not 
only in populations exposed to low arsenic levels (<1 ppb 
in drinking water), but also in populations exposed to high 
arsenic levels (>1000 ppb) (Petito-Boyce et al., 2008). Although 
these  populations  differ  significantly  in  development  of 
chronic effects of arsenic, acute lethal toxicity requires large 
amounts more of arsenic in either population.
Indeed, if it were so (as additivity to background demands) 
that there are members of the population just on the verge 
of thresholds for the tolerable state of internal variables, and 
that small exposures can shift those variables, then there 
should be no distinction between acute and chronic toxic-
ity. For a hypothetical person on the verge of the threshold, 
even a small one-time exposure might be all it takes to move 
the internal state just enough to cross the threshold, and so 
toxicities that appear in some people only after prolonged, 
ongoing, and substantial exposure should appear in those on 
the verge of response after only momentary small exposures. 
The fact that we do indeed recognize distinct modes of acute 
and chronic toxicity, and that agents cause different out-
comes from short and prolonged exposures, argues against 
the generality of the needed assumptions for additivity to 
background (Rodricks et al., 2007).
The no-threshold proposal is at variance with basic tenets 
of homeostasis—the robust nature of living systems
NRC (2009) suggested that threshold-based tolerance to a 
chemical may not exist in individuals who have reduced or 
no capacity to deal with that chemical. This is often described 
as infinite sensitivity (i.e., there is no dose so small that it will 
not affect some person in the population) and has been sug-
gested to be caused by other stressors (e.g., background expo-
sure to chemicals, physical stressors, presence of disease) that 
diminish capacity in individuals or genetic factors that result 
in a subpopulation of already ill individuals that respond to 
any added exposure.
Organisms are continually faced with changing circum-
stances and surroundings, including variations in diet and 
exposure to environmental substances. The internal milieu 
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pH, chemical concentrations, DNA integrity, and a host of 
other factors) than that prevailing in the external world, and 
this difference must be maintained by the constant expendi-
ture of energy lest the forces of thermodynamic equilibration 
destroy the special structures, compositions, and interactions 
that constitute the living state (NRC, 2007a). At the level of 
cells and organelles, it is the maintenance of different states 
inside and outside, as well as from cell to cell, that give them 
their functional properties; an orderly, purposeful control 
of such states and their transitions to alternative settings as 
needed is essential, and the ability to maintain that order is 
paramount (Goodman et al., 2010).
This includes, but goes beyond, homeostasis and feed-
back mechanisms. As systems-biology approaches to under-
standing organisms’ functioning become more prominent 
in our investigations of physiology, its modulation and per-
turbation, it becomes ever clearer that complex interacting 
gene expression networks embody stabilizing functions that 
lessen the impact of fluctuations and steer the overall state 
toward one of a few rather discrete states, with switching 
from one stable state to another effected by pronounced 
and carefully modulated signals (Ideker et al., 2001; Lusis, 
2006; Conolly and Thomas, 2007). It is typical for compo-
nent processes to be stimulated by one type of molecule and 
inhibited or undone by another, with the overall state being 
maintained by feedback processes that tune the outcomes 
to desired levels.
It is a fundamental property of living systems that they have 
extensive means to buffer their internal physiological state 
against the effects of changes the environment might tend 
to have on them (e.g., the ability to deal with free radicals, 
reactive oxygen species, and reactive products produced in 
the normal metabolism of food; Kemper et al., 2007). Indeed, 
the ability to control and appropriately modulate the inter-
nal physiological state, and not to have that state be buffeted 
about by changes in the external environment or elsewhere 
in the organism, is often named as one of the defining proper-
ties of life (Sadava et al., 2009). It is this process that ceases at 
death, and this cessation is quickly followed by deterioration 
and decay as the thermodynamic equilibrium formerly held 
at bay takes its course.
This robustness of the living system in the face of environ-
mental perturbations—this ability to carry on life processes 
in an appropriate and orderly way despite the day-to-day 
and  moment-to-moment  fluctuations,  novelties,  trends, 
and vicissitudes of impinging forces—comes to bear on the 
threshold question in two ways. First, the robustness is part 
of the organism’s “defenses” that the threshold model deems 
in need of being overwhelmed if a dose is to be large enough 
to cause toxicity (Sielken and Stevenson, 1998; Rhomberg, 
2004). The defenses are not merely detoxification and seques-
tration of the agent; they also include the resistance of the 
biological system to being unduly changed by the agent’s 
presence. It is when the ability of the system to counter that 
impingement becomes exhausted that the changes of control, 
and thus of functioning, become evident, and the dysfunction 
and destruction characteristic of toxicity begins. Thus, the 
existence of the robustness mechanism embodies the basis 
of the exposure threshold, and the mode of its failure defines 
the nature of the toxicity that ensues.
Strictly speaking, the additivity-to-background argument 
does not deny that this kind of systemic stability and homeos-
tasis operates and indeed that it constitutes the way in which 
those individuals who are not especially sensitive manage to 
tolerate exposures to the chemical in question. The assertion 
is that individuals vary in these properties sufficiently that, at 
least in some of them, the resistance to environmental pertur-
bation is so minimal that even small exposures to a chemical 
overcome the defenses. The counter to this line of argument 
is that we do not in fact observe this degree of variation—we 
do not see continuous and gradual gradation between people 
with normally functioning physiology (with some range of 
variation, but always adequate to maintaining basic function-
ing) and those who cannot maintain internal states in the 
face of environmental fluctuation or cannot coordinate their 
cells to function as tissues or cannot carry out basic life proc-
esses. It is not that individuals who have such problems do 
not exist; it is rather that such individuals are recognized as 
having a distinct state of disease, with specific causes of those 
diseases, and there is not a gradual gradation of such people 
with the general population such that health and disease are 
but extremes on a continuum.
The second way that robustness comes to bear on thresh-
olds is that its existence contradicts a needed assumption for 
the additivity-to-background argument: namely, the notion 
that small exposures to an agent will cause corresponding 
shifts in the distribution of some key internal physiological 
variable, pushing some individuals who are just on the margin 
of an acceptable value over the limit to a value that engenders 
toxicity. In view of robustness, it is not clear that small doses 
will indeed shift such a distribution. Although the value of the 
key internal variable may vary among individuals, for any one 
individual it will tend to be controlled by that person’s set of 
feedback and homeostatic processes, and accordingly it will 
be resistant to change from that value. That is, the additivity-
to-background argument, when applied to noncancer toxic-
ity, requires that the agent act on the value of the underlying 
physiological variable without a threshold. But in fact, as with 
the apical toxicity endpoint, the component physiological 
processes have robustness to small forces acting on them, 
and they will require a certain amount of force to overcome 
this  resistance  to  change  (Stebbing,  2003,  2009;  Rodricks 
et al., 2007). (It has also been argued that some responses can 
be hormetic, meaning there is a statistically or biologically 
significant decrease in adverse effects below the background 
effect in the low-dose region. A hormetic response in any low 
dose-response assessment would necessitate a threshold for 
an adverse effect at higher doses, and would obviate a linear 
low-dose approach [Dourson and Haber, 2010].)
The additivity-to-background argument fails to support 
general linearity. To conclude that the end result of a bio-
logical process is linear, one must start by assuming that the 
underlying processes sufficient for (and not merely risk fac-
tors of) disease are linear; thus, one would be assuming what Linear low-dose extrapolation for noncancer health effects    11
one is trying to prove. This is obviously circular reasoning. 
One must also assume that an agent will cause an effect, at 
even the smallest dose, and this assumes that there are no 
homeostatic or defensive mechanisms to regulate the biologi-
cal process in question. This is tantamount to assuming that 
one-one millionth of a gram of aspirin would be sufficient to 
cause metabolic acidosis or gastrointestinal (GI) hemorrhage 
in at least some exposed people. Although low-dose linear-
ity could occur under some circumstances, the assumptions 
would be very particular and do not likely apply in most 
circumstances.
In  the  end,  the  simple  view  of  noncancer  toxicity  as 
expressed in the additivity-to-background argument—that 
toxicity hinges on the sliding value of a single underlying 
key  physiological  variable—oversimplifies  the  question. 
A real understanding of noncancer dose-response entails 
embracing the complexity of underlying processes. Toxicity 
(whether cancer or other endpoints) is a multistep process. 
One molecular or cellular event or slightly altered physi-
ological variable does not result in a toxicity endpoint being 
manifested (Rhomberg, 2004). Multiple molecular and cel-
lular changes and events, each with their own threshold 
and dose-response, are necessary to produce the cancer or 
noncancer effect. In addition, the role of repair and detoxi-
fication in toxic process must be considered. Finally, effects 
are temporal in nature and are also sequential, in that actual 
modes of toxic action entail initial perturbations, adaptive 
responses  to  those  perturbations  (designed  to  minimize 
alteration of physiological control), and initial failures at 
lower levels of organization, which only if prolonged lead to 
a further cascade of failures that ultimately manifest them-
selves as sufficient overall dysfunction to be considered an 
adverse apical endpoint.
Population heterogeneity
White et al. (2009) asserted that heterogeneity in sensitiv-
ity to environmental chemicals in the population tends to 
“linearize” the dose-response curve. They suggested that a 
linear function for the population will result even if dose-
response  associations  are  not  linear  in  individuals.  They 
referred to the argument put forth by Lutz (1990 94–3541) 
regarding cancer and suggested that this argument holds for 
noncancer effects as well. Lutz (1990, p. 1246) claimed that 
because “sensitivity is governed by a number of genes, the 
dose-response curve becomes flatter with each modulatory 
factor (Figure 4 [reproduced here as Figure 1]). When the 
number of factors is increased ad infinitum, linearity results 
between the spontaneous tumor incidence and the high dose 
incidence. Although this situation cannot be reached in real-
ity, the linearizing effect of population heterogeneity might be 
sufficiently strong to account for the fact that dose-response 
curves in most human epidemiological studies do not show 
significant deviation from linearity.”
This argument does not actually hold for carcinogenesis, 
much less noncancer health effects. Lutz (1990) presented 
a widely cited diagram to illustrate his assertion, but it is 
only an illustration and is not (nor was it intended to be) the 
outcome of an analysis or the application of an established 
principle. Yet there is a mathematical principle applicable 
to this situation: using Lutz’s line of reasoning leads to the 
conclusion that heterogeneity in population sensitivity leads 
to a lognormal, not a linear, curve.
There are two issues with applying Lutz’s reasoning to the 
shape of the dose-response curve. The first is structural—
under the tolerance-distribution approach, dose-response is 
itself an expression of heterogeneous susceptibility. That is, 
dose-response curves show the distribution among members 
of the population in their individual level of sensitivity to a 
chemical; at higher and higher doses, a smaller and smaller 
proportion  of  the  population  can  tolerate  the  exposure 
  without ill effect (because their personal thresholds have not 
been exceeded). When dose-response patterns are observed 
in data, they are direct manifestations of the variation in 
 sensitivity and the operation in the population of factors alter-
ing that sensitivity. In other words, in experimental investiga-
tions of toxicity, variations in the individuals responding at 
different doses provide data on population variation in sen-
sitivity. Accordingly, it is not clear what it would mean to have 
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Figure 1.  Schematic representation presented by Lutz (1990) of dose-
response  relationships  in  heterogeneous  populations,  with  increasing 
factors affecting sensitivity to a chemical carcinogen in each graph.12     L. R. Rhomberg et al.
factors to be superimposed on an observed   dose-response. 
How are those factors to be viewed as additions to or outside 
influences on the operation of the set of sensitivity variations 
that led to there being an observed dose-response relation-
ship in the first place?
The second issue is that the combined action of multiple 
sensitivity factors is not to linearize the dose-response curve, 
but to make it lognormal. The best way to regard the action of 
sensitivity factors is as multiplicative modifiers. For example, 
if a difference in uptake of a chemical alters a biological event 
in a disease process 3-fold and differences in metabolism 
alter it 5-fold, then combined, this would lead to a 15-fold 
difference in biological events leading to disease. Each fac-
tor magnifies or lessens the rates of processes responsible 
for tolerance or susceptibility. The combined effect of many 
independent multiplicative factors, according to the central 
limit theorem, is to produce a lognormal distribution of sensi-
tivity. As stated by Morgan et al. (1990, p. 89), “The lognormal 
distribution applies as the limiting case for multiplicative 
quantities due to the approach to normality of the sum of 
the logs.”
The applicability of this theory was demonstrated by Hattis 
et al. (2001), who created a database of quantitative observa-
tions of parameters likely to affect responses to particles. This 
study was based on epidemiological studies of methacholine, 
flour dust, and other agents that induce acute changes in 
lung function. These investigators found that lognormal dis-
tributions provided a good description of their vast data set. 
Although the slopes of the lines describing the data covered a 
considerable range, perhaps reflective of measurement errors 
or differences in populations in the different studies, these 
investigators reported an absence of any systematic depar-
tures from the expected lognormal distributions in the data 
sets, and supported the use of a simple distributional model 
for risk projections.
Based on basic principles and actual data, it is evident 
that heterogeneity in the population regarding sensitivities 
to chemicals will not lead to a linear dose-response curve. 
Rather, the multiplicative effects of the factors that affect sen-
sitivity result in a lognormal curve.
Exposure measurement error
White et al. (2009) cited some epidemiological studies that 
appear to show linear/no-threshold exposure-response pat-
terns even when corresponding studies conducted in labo-
ratory animals, using relatively similar exposure regimens, 
suggest otherwise. They interpreted these results as demon-
strating the linearization of exposure-response in heteroge-
neous human populations; that is, the observation served for 
them as a confirmation in observational outcomes of their 
proposal that additivity to background and population heter-
ogeneity effectively negate any threshold or nonlinear pattern 
that might be inherent in the toxicity mode of action. Further, 
in responding to a critique of White et al. (2009), Burke et al. 
(2009) stated, “Although [a small range of exposures and 
measurement  error]  need  to  be  considered  in  evaluating 
epidemiologic study results, modeling techniques such as 
nonparametric smoothing methods have demonstrated the 
capacity to identify potential threshold relationships even in 
the context of relatively extreme measurement error (Cakmak 
et al. 1999; Schwartz and Zanobetti 2000).”
It is well recognized in the regression literature, however, 
that measurement error in the independent variable gen-
erally biases the observed functional relationship with the 
dependent variable toward a more modest and flatter trend 
than is actually the case (e.g., Carroll et al., 2006; Kuha and 
Temple, 2003; Crump, 2005; Küchenoff and Carroll, 1997). 
The measurement error need not be biased itself; the simple 
fact that the placement of individual observations along the 
x-axis is “smeared out” (since the measured values place 
them randomly higher or lower on the axis than their true 
position, owing to the imprecision of the measurements) 
tends to obscure any inflections in the functional relation-
ship and makes it appear more linear than it truly would be 
seen to be if the dependent variable were measured without 
such errors. It is important to recognize that the issue here 
is not simply that studies may have poor statistical power 
to show that nonlinearities are significantly supported over 
alternative linear model fits (although that issue also exists), 
but rather that exposure measurement error can artificially 
give the appearance of linearity to an exposure-response 
relationship that is truly sharply nonlinear or even threshold 
in nature.
In  epidemiological  studies  of  exposure-response  pat-
terns, the independent variable is the exposure measure, and 
measurement uncertainty in individual exposures is typically 
pronounced. This is especially so for criteria air pollutants, 
such as PM, for which exposures for nearby individuals may 
be estimated using results at centrally located air-monitoring 
stations. Exposure measurement error can result when con-
centrations of the pollutant measured at central monitors 
are not representative of personal exposures to the pollutant. 
Reasons for this include uneven distribution of PM attrib-
utable to local sources; monitoring sites may represent a 
nearby source and not human exposures a small distance 
away; pollution patterns can be affected by terrain features 
and weather; and daily variations in PM concentrations at 
a central monitoring site may differ from variations experi-
enced by individuals (US EPA, 2009). Even when personal 
exposures can be measured more directly, they typically 
represent “snapshot” determinations at a particular moment 
in time, and each such single measurement is an uncertain 
indicator of the long-term past cumulative or average expo-
sures for the individual in question, yet it is these long-term 
past exposures that are at issue for many toxic responses 
that  are  being  evaluated  for  a  population  of  individuals. 
Moreover, differences from person to person in the relation-
ship between externally measured exposure and the internal, 
target-organ biologically effective dose will lead to further 
exposure measurement imprecision. Even in the unlikely 
event in which all individuals in a population have the same 
true concentration-response threshold, exposure measure-
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affected below this threshold and others appearing not to be 
affected even above their true threshold. Thus, thresholds in 
the relationship between individual exposures and risks of 
morbidity and mortality may be blurred by measurement 
error when studied by using the relationships between con-
centrations at central-site monitors and aggregate morbidity 
or mortality (Daniels et al., 2004).
Because of the prevalence of exposure measurement error 
in epidemiological data, conclusions about the linearity of 
the exposure-response curve must be examined carefully and 
treated with some skepticism. The study that best illustrates 
the effects of measurement error on assessing thresholds was 
that by Brauer et al. (2002), who conducted simulations in 
which a strict population threshold at various levels of expo-
sure was assumed, and then the effect of measurement error 
on the ability to detect that threshold, or even a nonlinear 
exposure-response pattern, was assessed (Figure 2). It is note-
worthy that Brauer et al. (2002) estimated the magnitude of 
exposure measurement error (which was assumed to be unbi-
ased) based on actual studies of criteria pollutants (measured 
ambient and personal PM2.5 and sulfate concentrations)—
that is, the magnitude of uncertainty in individual exposure 
measurements was drawn from actual cases of agents for 
which apparently linear dose-response patterns have been 
claimed. These investigators found that estimating individual 
exposure to air pollutants from central-site outdoor pollution 
monitors may result in considerable error. They reported that 
some individuals in the population will have greater expo-
sures than others for any given central-site ambient concen-
tration, which will broaden the normal distribution of risks 
due to interindividual variability in exposure.
The Brauer et al. (2002) simulations set the true exposure-
response curve (i.e., true personal exposure versus response) 
by assumption, using strict thresholds shared by all members 
of the population that were set at various exposure levels 
together with a linear rise in risk above this threshold. They 
then  simulated  the  exposure-response  relationship  that 
would be found by a study in which each true curve was 
affected by exposure measurement error of the magnitude 
actually observed to occur in real studies. They showed that 
if exposure measurement error could be reduced by the use 
of  appropriate  exposure  metrics,  then  common  underly-
ing individual thresholds result in similar population-level 
thresholds. But at the levels of exposure measurement error 
actually  found  in  criteria  pollutant  epidemiological  stud-
ies, the simulated exposure-response curves looked linear 
even when the specified true curves had thresholds. (See 
Figure 2, drawn from their paper.) It was further shown that 
the obscuring of thresholds would be greater if the simula-
tions incorporated thresholds that varied among individu-
als (yet for which there was nonetheless a strict population 
threshold below which no person responds). The simulations 
of Brauer et al. (2002) suggested that the inability to detect 
a threshold in many epidemiological studies does not, in 
fact, mean that no threshold exists. The apparent linearity 
of observed   exposure-response relationships in studies with 
prevailing levels of exposure measurement error is explicable 
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Figure 2.  Simulation results reproduced from Brauer et al. (2002). The graphs show ambient concentration of PM2.5 (μg/m3) on the x-axis and the expected 
number of deaths per 1, 000, 000 on the y-axis. The true underlying individual thresholds are indicated on the graphs as triangles.14     L. R. Rhomberg et al.
It has been suggested that robust epidemiological inves-
tigations  have  shown  that  thresholds  are  not  generally 
observed for noncancer outcomes, citing studies of radia-
tion, secondhand tobacco smoke, nitrogen and sulfur oxides, 
PM, ozone, and lead (White et al., 2009). To use PM as an 
example, in its most recent Integrated Science Assessment, 
US EPA (2009) evaluated newly available evidence to assess 
a population threshold value for health effects. They cited 
studies by Daniels et al. (2004), Schwartz (2004), and Samoli 
et al. (2005), which assessed associations between short-term 
PM2.5 exposure and mortality rates, and the Schwartz et al. 
(2008) study, which assessed association between long-term 
PM2.5 exposure and mortality rates. US EPA (2009) concluded 
that  these  studies  consistently  found  that  a  no-threshold 
log-linear model adequately portrays the PM concentration 
excess mortality response relationship in multicity analyses, 
although uncertainty exists on a city-to-city basis because of 
heterogeneity in the exposure concentration-response curve 
across cities.
Burke et al. (2009) cited the Cakmak et al. (1999) and 
Schwartz and Zanobetti (2000) studies as evidence of mod-
eling  techniques  that  can  identify  potential  thresholds  in 
exposure-excess risk relationships. Although Schwartz and 
Zanobetti (2000) argued that it is possible to detect thresh-
old relationships in meta-analyses down to low concentra-
tion levels, they did not actually directly address the effect 
of measurement error on the shape of the concentration 
excess  response  within  individual  cities  upon  which  the 
meta-analyses were based. Cakmak et al. (1999) evaluated 
whether  nonparametric  smoothed  representations  of  the 
association between air pollution and mortality could dis-
tinguish between linear and threshold models in the pres-
ence of measurement error. The investigators dealt only with 
population-level data, however, and did not directly address 
the impact of individual measurement error on the shape of 
the concentration-response curve. In addition, they showed 
that with simulations of threshold models, although a thresh-
old model was selected over a linear model the majority of the 
time, this “majority” ranged from 52% to 90%, depending on 
the exposure error and threshold concentration in the simu-
lated data. Thus, between 10% and 48% of the time, a linear 
model was incorrectly chosen over a threshold model.
Although exposure measurement error may not always 
be large enough to appear to linearize a truly threshold 
dose-response relationship, it is important to bear in mind 
that this bias exists and that, in simulations, the degree 
of bias known to apply to actual studies is sufficient to 
produce  a  false,  apparently  linear  exposure-excess  risk 
result. That is, it is not just an issue of statistical power to 
detect nonlinearity, but rather that exposure measurement 
error biases towards finding flatter, more linear exposure-
response relationships than the actual underlying truth. 
This has not only been shown by Brauer et al. (2002), but is 
a generally recognized statistical principle that uncertainty 
in an independent variable generally flattens a regression 
curve (Zeger et al., 2000). Because exposure is the inde-
pendent  variable  in  an  exposure-response  relationship, 
measurement error leads to uncertainty, which then leads 
to a flattening of the curve.
Even if one were to adequately address issues of expo-
sure measurement error, there could still be other meth-
odological issues that could affect the interpretation of an 
exposure-response analysis. For example, confounders (e.g., 
co-exposures to other agents, diet, genetics, socioeconomic 
factors, or lifestyle) may not adequately be accounted for or 
disease ascertainment may not be robust. These factors could 
impact the exposure-response model chosen.
Many factors can mask a threshold for exposure-excess 
disease risk in human studies, so it is critical that mode of 
action for the agent in question be considered. If a threshold 
is not detected in a human study, but there is a scientifically 
valid reason based on the mode of action for the agent that the 
effect is of a threshold nature, then one must conclude that 
apparent differences in the concentration-response function 
shape between human data and animal studies relates not to 
actual linearity in humans (as White et al. [2009] argue), but 
rather to this artifactual flattening, which can be detected by 
observing the mode of action and its nonlinearities in ani-
mal experiments, where exposure measurement error can be 
minimized.
Questions for further discussion
The abandonment of a threshold approach to noncancer risk 
assessment is an enormous step, and it is important that the 
underlying assumptions and implications of any new meth-
odology be fully understood before rash alterations are made. 
The questions about what to expect from low exposures for 
noncancer endpoints for noncancer toxicity, and how varia-
tion in the population and heterogeneity in sensitivity impact 
the potential impact of additivity to background and other 
matters, are not simple. We have attempted to more explicitly 
address underlying assumptions and relevant available data 
as a basis to consider more fully low-exposure linearity in 
further dialogue and exploration.
The larger problem we face in noncancer human health 
risk assessment is that we seek insight into the potential for 
low levels of exposure to cause harm to humans, and we must 
use as a basis for such judgments the observations from haz-
ards evident at much higher exposures, often in animals. The 
human risks at low doses, if they exist, are too rare to observe 
directly, and so inferences must be made that depend for 
their  validity  on  invoking  wider  biological  understanding 
of what should be expected to occur at low levels of human 
exposure. Our main need is to extrapolate downward from 
observed effects at high doses, using the presumption that 
the dose-response pattern seen in animals is giving us useful 
information about the human dose-response pattern and its 
lower dose range.
In  view  of  this,  it  is  important  that  the  additivity-to -
background  argument—the  lynchpin  of  the  proposal  to 
apply low-dose linearity to noncancer risk assessment—is 
an assertion of the existence of a linear component to the 
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That is, it is about extrapolating upward from the zero-dose 
point rather than downward from observable responses or 
points of departure. Even if one were to accept that such an 
effect happens at near-zero exposures (and we have taken 
issue above with the main arguments that suggest this is gen-
erally so), it remains that the existence-in-principle near zero 
dose has little to say about the magnitude of the risk or how 
far upward from zero dose one can go before any theoretical 
linear component is overwhelmed by the nonlinear aspects 
of the mode of action of most noncancer endpoints. Because 
the reason for the existence of such a near-zero linear com-
ponent has to do with the pattern of variation in sensitivity 
in the subject population, it is human background diseases 
and human variations in the values of underlying contrib-
uting factors that are at issue, and animal studies provide 
little information about these. The dose-response pattern 
observable in animals depends on interindividual variation 
in animals rather than in humans, and moreover in the cen-
tral and least-sensitive part of the animal variation range, not 
the most-sensitive end that is at issue for additivity to back-
ground. In our evaluation of the linearity question, we have 
focused on a critical look at the arguments for the existence of 
a low-dose linear component, but even if such a component 
is accepted, many further questions will need to be examined 
if one is to know how to make use of this principle to address 
how to conduct top-down, animal-to-human dose-response 
inferences, and a number of consequences, many apparently 
unintended, would arise if linear extrapolation from points 
of departure were adopted as a science policy (Rhomberg, 
2010).
There are some particular larger questions that we think 
deserve  deeper  examination  and  wider  discussion.  One 
is the issue of “harmonization” of cancer and noncancer 
exposure-response approaches for risk assessment purposes 
(Bogdanffy et al., 2001; Barton et al., 1998; Rhomberg, 2004). 
Although one can hardly be against harmony and for discord, 
it is important to realize (taking the metaphor of “harmony” 
as a model) that harmonization does not mean that an iden-
tical method needs to be applied to all cases for all agents 
and disease endpoints. Indeed, in the musical definition of 
harmony, the point is that all the notes are not identical; dif-
ferent notes complement one another and are compatible. 
The combination of different, yet harmonized, notes allows 
for a greater richness in the music by drawing on a larger har-
monic framework with which each note is compatible but 
no note is identical. “Harmonization” should mean stressing 
compatibility of inferences about underlying pharmacokinet-
ics and modes of action and using the insights developed in 
dissecting the underlying biology of different endpoints to 
inform our understanding across endpoints.
Clearly,  in  selecting  exposure-response  methods,  we 
should aim at approaches that are not contradictory or incom-
patible, but this does not mean that they should be identical. 
There are notable differences between some cancer and non-
cancer responses that lead to different primary reasons why 
a changing response rate with increasing dose is observed 
(Rhomberg, 2004). In cancer, the issue has traditionally been 
the greater probability of the confluence of a number of all-or-
none events, each of which happens with a dose-dependent 
probability. Response is largely a matter of chance as to which 
individual cells achieve the requisite set of genetic changes, 
and the modeling of such chance events (among individuals 
who are not otherwise notably different) is often assumed to 
be the driver of the dose-response phenomenon. It is now 
recognized, however, that some carcinogenic events—such as 
mutation, homeostasis, DNA repair, and checkpoint control—
may in fact have thresholds. This is recognized in US EPA’s 
cancer guidelines (US EPA, 2005), which suggest a nonlinear 
approach to cancer risk assessment when carcinogenesis 
occurs via a mode of action that is not linear at low doses. 
For typical noncancer endpoints, in contrast, the effect is on 
the collective function of all the molecular pathways, cells, 
and tissues that are involved in the relevant physiological 
processes and the endpoint. Toxicity manifest as noncancer 
endpoints essentially consists of the consequences of dys-
function of the whole physiological system, not of failures 
of any particular cell or gene. The component physiological 
processes vary continuously, according to the sum of the 
functioning of all the cells and molecules in the tissues in 
question in processes that are characterized by homeosta-
sis and active controls to maintain and properly modulate 
desirable states in the face of environmental stresses. Toxicity 
consists of the failures of overall control, and stages of the 
process can be recognized, from adaptive and compensatory 
processes that are the signs of the successful operation of the 
control processes through adverse dysfunction and finally, to 
frank toxicity. It is a basic characteristic of living things that 
they maintain controlled internal states in the face of external 
fluctuations in their environments, fluctuations that include 
uptake of small amounts of substances from the external 
world. The nature of biochemical machinery, with extensive 
feedback and control processes and means for orderly and 
purposive changes in state, is geared to providing the means 
for organisms not to be buffeted about into adverse states 
by small environmental stressors, and a good proportion of 
energy use by living systems is devoted to maintaining such 
controlled states that differ from and retain independence of 
the surrounding environment. Toxicity should be seen as the 
failure of such processes, and the effect of low stressor levels 
needs to be tied to the nature of those failures.
The recent NRC report, “Science and Decisions: Advancing 
Risk Assessment” (NRC, 2009),     noted that cancer exposure-
response  is  driven  by  a  stochastic-event  approach  but 
does not incorporate information on individual sensitivity, 
whereas the noncancer toxicity exposure-response approach 
is driven by considerations of individual sensitivity differ-
ences but does not treat stochastic elements. The NRC report 
advocated incorporating both approaches into all exposure-
response assessments in the interest of harmonization and 
consistency. Although this seems like a good idea in princi-
ple, the underlying assumptions need to be stated and further 
explored. Moreover, the practicality is that exposure-response 
data from experimental studies typically have few exposure 
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a sufficient number of parameters by fitting models to data; 
the  current  dichotomy  of  approaches  toward  cancer  and 
noncancer endpoints reflects the attempt to devote the few 
dose-response curve parameters that may be set by fitting to 
data to the characterization of the main processes that are 
felt to be the dominant determinants of the modulation of 
response level with differing exposures. As a basis to mean-
ingfully develop a harmonized approach further, the nature 
of appropriate data to best inform suggested approaches will 
need to be considered. A simple multiplying of distributions 
seems unwarranted—if there is indeed interindividual varia-
tion in sensitivity to the causation of component events, then 
the variations in the events themselves are what need to be 
characterized.
Another related question is to examine what it means to 
separate consideration of sensitivity from dose-response for 
a noncancer endpoint. As noted above, variation in sensitivity 
has, in existing practice, been considered as the reason for the 
observed dose-response—that is, as the basis for the increas-
ing proportion of responders at higher doses. Considering 
dose-response for an individual of specific sensitivity invokes 
an  alternative  determinant  of  response.  Stochastic  event 
models of noncancer toxicity have not been developed, and 
it is not immediately clear how such models would relate to 
the biological causes of the events they aim to describe.
As  the  issue  of  harmonization  of  risk  assessment 
approaches is debated, it is important to ask what is the pri-
mary objective of the risk assessment endeavor. The authors 
of this paper are evaluating the potential overall health impact 
of exposure to multiple agents that may produce multiple 
endpoints. The impact of these different endpoints (cancers 
and the different noncancer effects for individuals and popu-
lations) are not the same. Thus, it does not make sense to use 
the same approach to model the effects.
Finally, we must return to the motivations for the proposal 
to undertake linear low-exposure extrapolation as a general 
default procedure. As we have stated, we do not think such 
an  approach  is  scientifically  justified  or  supported.  One 
motivation is to base characterization of potential impacts 
of small exposures on a precautionary basis, raising theo-
retical possibilities that can be abandoned if sufficient proof 
against them is adduced. We caution that, aside from the lack 
of scientific justification for such an approach, it is not at all 
clear that adoption of universal low-dose linear assessment 
approaches is indeed precautionary. The arguments adduced 
for such linearity are arguments in principle—they do not 
provide the basis for estimating the magnitude of any such 
effect, and it is not clear how to do so in a meaningful way. 
Moreover, since all substances show toxicity at sufficiently 
high doses, it would follow from the all-is-linear approach 
that all exposures to all agents bear some risks. It is not at all 
clear that action against one hypothetical risk (by restricting 
exposure on a precautionary basis) would not increase over-
all risk by inducing added risks from the inevitable increases 
in other exposures to other agents that any restriction on a 
single substance would entail. Since the magnitude of the 
hypothesized  risks  cannot  readily  be  estimated,  one  has 
a hard time assuring that actions against single exposures 
produce an overall public health benefit.
Another motivation is to enable risk management evalua-
tions that adjust levels of exposure restriction by the degree of 
public health benefits they produce. To assess the benefits of 
regulation or to judge how trade-offs are best made requires 
a measure of continuous change in marginal impact with 
marginal changes in exposure—i.e., at least local approximate 
linearity. We note, however, that such analysis is only useful 
if it applies to the range of cases being evaluated, and it need 
not apply universally. We suggest developing approaches 
that examine exposure-response relationships at the upper 
reaches—near the clear effect levels—and to do so case by 
case,  bringing  understanding  of  chemical-specific  modes 
of action to bear, to address such questions, rather than to 
invoke a universal principle of questionable scientific sound-
ness and severely limited practical utility to the question that 
motivated it.
Conclusions
Recently, a proposal has been put forth that additivity to back-
ground disease and heterogeneity in sensitivity to chemicals 
in the population is best characterized by linear exposure-
response relationships for noncancer health effects at low 
exposures, and that this is demonstrated in epidemiological 
studies that show no evidence of a threshold for noncancer 
health effects (White et al., 2009; NRC, 2009). Assumptions that 
form the basis for the hypotheses of additivity to background 
disease and heterogeneity and epidemiological studies that 
appear to show linear no-threshold  exposure-response rela-
tionships have been critically examined as a basis for more 
robust consideration of the proposal. Specifically, fundamental 
biological and biochemical processes—such as homeostasis, 
nonlinear signal processing, and the law of mass action—
influence and govern exposure-dependent responses to both 
endogenous and exogenous substances, and to both “toxic” 
and “therapeutic” agents, and need to be carefully considered 
and appropriately weighted against potentially policy-based 
supposition. The development of advanced therapeutics has 
resulted from increased knowledge of molecular and biologi-
cal processes brought about by advances in chemistry and 
biology. Similarly, advances in the use of toxicological and 
epidemiological data in risk assessment should be driven by 
evidence-based  knowledge  of  fundamental  biological  and 
chemical principles. As discussed here, the default assump-
tion of low-exposure linear extrapolation of toxicity observed 
at high exposures in all cases does not comport to modern-day 
scientific knowledge of biology and in the absence of compel-
ling science-based justification.
For both cancer and noncancer responses, default risk 
assessment procedures are decades old and poorly reflec-
tive of current knowledge of biology or of adaptive cellular 
pathways, particularly those related to the evolution of stress 
response pathways that protect all cells and organisms from 
modest  increases  in  concentrations  of  compounds  with 
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(Simmons et al., 2009). NRC published two documents in 
2007, “Toxicity Testing in the 21st Century: A Vision and a 
Strategy” and “Applications of Toxicogenomic Technologies 
to Predictive Toxicology and Risk,” both of which argued that 
new testing approaches need to be developed to evaluate 
perturbations of human toxicity pathways and to evaluate 
when perturbations are likely to become sufficiently large to 
pose a health risk. These documents put forth that all toxic-
ity pathways (including cancer) have multiple stages that are 
defined events, and that nonlinearity or thresholds in any 
step will introduce nonlinearity and thresholds in all subse-
quent steps, including the apical effect. It also asserted that, 
even if each step is linear, extreme nonlinearity in the dose-
response relationship for later steps and apical endpoints 
will result if there are no background frequencies of indi-
viduals at the penultimate stage. In addition, the increasing 
use of genomic tools is tending to show that thresholds for 
key events beyond general stress happen at doses close to 
the doses at which histological effects are observed (even 
for carcinogens), and at lower doses, several new studies 
suggest changes are general stress changes, whereas there 
are no changes in gene regulation (e.g., see Naciff et al., 
2005). At later stages closer to the apical effects, more sys-
tems in the body (and hence higher levels of organization) 
are affected. Thus, later stages could have more interactions 
with disease processes, chemical-disease interactions would 
not be expected in the early stages of the toxicity pathway, 
and thresholds in processes in stages prior to the stages in 
common with disease processes will result in thresholds for 
that chemical. Based on these principles, one must conclude 
that thresholds are the rule (NRC, 2007a, 2007b).
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